ReviewJournal of the American Academy of Dermatology2022
DESCRIBE-AD: A novel classification framework for atopic dermatitis.
Review in Journal of the American Academy of Dermatology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed.
- Efficacy and Safety of Variable-Dose Versus Continuous-Dose Abrocitinib Treatment in Patients with Moderate-to-Severe Atopic Dermatitis: A Pooled Analysis.Dermatology and therapy · 2026Article
- Characterization of Prurigo Nodules in Adults With Moderate-To-Severe Atopic Dermatitis in Japan: A 2-Year Observational Study.The Journal of dermatology · 2026Observational
- Association Between Obstructive Sleep Apnea and Atopic Dermatitis in the Korean Adult Population: Results From the 2019-2022 Korea National Health and Nutrition Examination Survey.Allergy, asthma & immunology research · 2025Article
- Describing atopic dermatitis in real-world clinical practice: a retrospective health system analysis.Archives of dermatological research · 2025Article
- A Multidisciplinary Approach Is Beneficial in Atopic Dermatitis.Dermatology and therapy · 2024Review
- Ozonated Sunflower Oil (OSO) Alleviates Inflammatory Responses in Oxazolone-Induced Atopic Dermatitis (AD)-Like Mice and LPS-Treated RAW 264.7 Cells.Journal of microbiology and biotechnology · 2024Article
- Management of Patients Affected by Moderate-to-Severe Atopic Dermatitis with JAK Inhibitors in Real-World Clinical Practice: An Italian Delphi Consensus.Dermatology and therapy · 2024Article
- Advances in the study and application of digital technology in the clinical practice of atopic dermatitis.Digital healthReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
backgroundAtopic dermatitis (AD) is a chronic, inflammatory skin disease associated with heterogeneous morphology, distribution, symptoms, severity, extent, longitudinal courses, quality of life burden, comorbidities, and treatment responses. This heterogeneity contributes to challenges in diagnosis, the characterization of disease activity, and therapeutic stratification.
objectiveTo develop a framework to standardize AD assessment.
methodsWe propose a novel framework to assess AD based on a literature review and clinical experience.
resultsDESCRIBE-AD is a framework that can effectively capture the clinical domains contributing to AD heterogeneity and includes both patient- and clinician-reported perspectives. DESCRIBE-AD includes assessments of Dermatitis morphology and phenotype, Evolution of disease, Symptom severity, Comorbid health disorders, Response to therapy, Intensity of lesions, Burden of disease, and Extent of lesions. Rather than placing the focus on any single, specific aspect of AD, DESCRIBE-AD allows for a comprehensive approach to the assessment and clinical management of AD.
conclusionsDESCRIBE-AD is a novel framework that can be used to better describe the heterogeneity of AD and guide treatment decisions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.